KRYS

Krystal Biotech Inc

Apr 09 • 04:00PM ET

258.33

-5.89 -2.23 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB REGN VRTX BMRN INCY NBIX SRPT AXSM QURE

| Held by: IJR VTI VB IWM XBI VBK FBT VXF SPSM IJT

Index	RUT	P/E	37.74	EPS (ttm)	6.84	Insider Own	13.34%	Shs Outstand	29.19M	Perf Week	-0.22%
Market Cap	7.55B	Forward P/E	26.05	EPS next Y	9.92	Insider Trans	-6.12%	Shs Float	25.33M	Perf Month	-1.05%
Enterprise Value	6.73B	PEG	1.03	EPS next Q	1.48	Inst Own	95.94%	Short Float	11.40%	Perf Quarter	4.85%
Income	204.83M	P/S	19.41	EPS this Y	11.71%	Inst Trans	-1.35%	Short Ratio	9.65	Perf Half Y	41.15%
Sales	389.13M	P/B	6.18	EPS next Y	29.77%	ROA	17.14%	Short Interest	2.89M	Perf YTD	4.78%
Book/sh	41.78	P/C	9.12	EPS next 5Y	25.30%	ROE	18.91%	52W High	298.30 -13.40%	Perf Year	53.62%
Cash/sh	28.32	P/FCF	39.97	EPS past 3/5Y	- -	ROIC	16.69%	52W Low	122.80 110.37%	Perf 3Y	206.11%
Dividend Est.	-	EV/EBITDA	40.15	Sales past 3/5Y	- -	Gross Margin	92.50%	Volatility	3.32% 3.69%	Perf 5Y	272.82%
Dividend TTM	-	EV/Sales	17.30	EPS Y/Y TTM	127.79%	Oper. Margin	41.41%	ATR (14)	10.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.56	Sales Y/Y TTM	33.95%	Profit Margin	52.64%	RSI (14)	50.01	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	9.95	EPS Q/Q	11.65%	SMA20	1.55%	Beta	0.54	Target Price	324.78
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	17.52%	SMA50	-2.08%	Rel Volume	0.76	Prev Close	264.22
Employees	295	LT Debt/Eq	0.01	Earnings	Feb 17 BMO	SMA200	24.33%	Avg Volume	299.22K	Price	258.33
IPO	Sep 20, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.08% 1.67%	Trades		Volume	228,208	Change	-2.23%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	Wolfe Research	Peer Perform
Jan-06-26	Upgrade	Citigroup	Neutral → Buy	$309
Mar-05-25	Initiated	Jefferies	Buy	$245
Aug-06-24	Downgrade	Citigroup	Buy → Neutral	$195 → $204
Nov-20-23	Initiated	Goldman	Buy	$160
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$100
Oct-12-23	Initiated	Citigroup	Buy	$160
Sep-07-23	Initiated	Berenberg	Buy	$154
Apr-18-23	Initiated	Stifel	Buy	$102
Feb-28-23	Upgrade	Goldman	Neutral → Buy	$79 → $124
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$74
Jan-18-22	Initiated	BofA Securities	Buy	$110
Jul-20-21	Upgrade	Goldman	Neutral → Buy	$73 → $90
Sep-18-20	Initiated	B. Riley FBR	Buy	$100
Jun-04-20	Initiated	Evercore ISI	Outperform	$90
Sep-24-19	Initiated	Goldman	Neutral	$60
Aug-06-19	Reiterated	H.C. Wainwright	Buy	$56 → $59
Jun-24-19	Reiterated	H.C. Wainwright	Buy	$38 → $56
Jun-24-19	Reiterated	Chardan Capital Markets	Buy	$57.50 → $75
May-30-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Feb-28-26 02:21AM	Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 (Insider Monkey)
Feb-24-26 08:00AM	Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-21-26 06:32AM	Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating (Insider Monkey)
Feb-18-26 11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
04:44AM	Stock Market News for Feb 18, 2026 (Zacks)
04:01PM	Loading…
Feb-17-26 04:01PM	Krystal Biotech Inc (KRYS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:32PM	Krystal Biotech, Inc. Q4 2025 Earnings Call Summary (Moby)
10:42AM	Krystal Biotech Q4 Earnings Call Highlights (MarketBeat)
07:00AM	Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire)
Feb-14-26 05:00AM	Netflix Is Casting a Light on a Rare Disease. Pearl Jam's Frontman Is Raising Cash to Cure It. (Barrons.com)
Feb-13-26 05:15PM	Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-10-26 02:41PM	Biotech Stock Nears Entry After FDA News; Earnings On Horizon (Investor's Business Daily)
08:00AM	Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 (GlobeNewswire)
Feb-09-26 08:00AM	Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)
Feb-03-26 08:58PM	Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision (Insider Monkey)
10:11AM	Loading…
Jan-30-26 10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
Jan-28-26 08:48AM	5 Stocks With Recent Price to Strengthen Your Portfolio (Zacks)
Jan-27-26 12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
Jan-26-26 08:55AM	Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-23-26 12:00PM	Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice (Zacks)
Jan-22-26 02:31PM	Biotech stocks are among today's winners (MarketWatch)
02:16PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks)
10:31AM	FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
Jan-19-26 10:36AM	ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results (Zacks)
04:19AM	What Does Wall Street Think About Krystal Biotech (KRYS)? (Insider Monkey)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
09:06AM	Loading…
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
08:39AM	5 Stocks With Recent Price Strength to Maximize Your Gains (Zacks)
Jan-13-26 02:20PM	Moderna Stock Gets Healthy Relative Strength Rating Jump (Investor's Business Daily) +7.28%
01:28PM	ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook (Zacks)
Jan-12-26 02:07PM	KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives (Zacks)
Jan-11-26 01:00PM	Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 08:55AM	Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why (Zacks) +5.02%
Jan-08-26 10:02PM	Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path (MarketBeat)
04:01PM	Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis (GlobeNewswire)
09:44AM	KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? (Zacks)
Jan-07-26 04:05PM	Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis (GlobeNewswire)
Jan-05-26 08:00AM	Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-25 01:48PM	Moderna Stock Sees Healthy Relative Strength Rating (Investor's Business Daily)
Dec-16-25 02:09PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-15-25 02:59PM	Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Dec-05-25 11:30AM	Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? (Zacks) +5.48%
Dec-01-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-26-25 08:00AM	Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-18-25 04:45AM	Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT (Insider Monkey)
Nov-14-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-12-25 01:33PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
Nov-11-25 01:04PM	Syndax Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-03-25 04:01PM	Krystal Biotech Inc (KRYS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Global ... (GuruFocus.com)
07:00AM	Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Oct-31-25 09:18AM	Krystal Biotech Inc (KRYS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 10:00AM	CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 10:00AM	Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-21-25 08:00AM	Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis (GlobeNewswire)
Sep-30-25 10:18AM	Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? (Zacks)
Sep-17-25 09:27AM	Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-15-25 01:39PM	FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin (Benzinga) +8.37%
08:00AM	Krystal Biotech Announces FDA Approval of Updated VYJUVEK Label (GlobeNewswire)
Sep-12-25 08:39AM	TSCM U.S. Small Cap Growth Strategy Reduced Its Position in Krystal Biotech (KRYS) (Insider Monkey)
Sep-03-25 11:30AM	Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-25 08:00AM	Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-21-25 12:11PM	Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer (GlobeNewswire)
Aug-05-25 12:00PM	Krystal Biotech price target lowered to $182 from $192 at BofA (TipRanks)
08:59AM	KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook (Zacks)
03:02AM	Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-04-25 08:15AM	Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates (Zacks) -14.04%
07:00AM	Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results (GlobeNewswire)
Jul-29-25 10:00AM	Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:00AM	Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 (GlobeNewswire)
Jul-28-25 10:00AM	Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth (Zacks)
Jul-25-25 09:00AM	Krystal Biotech Announces Approval of VYJUVEK by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jul-24-25 08:00AM	Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté (GlobeNewswire)
08:00AM	Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Decollete (GlobeNewswire)
06:27AM	Dystrophic Epidermolysis Bullosa Market Analysis and Forecast, 2025-2035: Topical Therapies Dominate DEB Market as Vyjuvek Secures Leading Position (GlobeNewswire)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
Jul-09-25 07:00AM	Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis (GlobeNewswire)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-25-25 11:17AM	KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study (Zacks)
09:55AM	Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? (Zacks)
Jun-24-25 07:00AM	Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jun-05-25 11:30AM	Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report? (Zacks)
Jun-03-25 08:00AM	Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-02-25 11:04AM	Implied Volatility Surging for Krystal Biotech Stock Options (Zacks)
May-14-25 08:30AM	Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore (MarketBeat)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-09-25 10:30AM	Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-07-25 08:00AM	Krystal Biotech to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
03:08AM	Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-06-25 01:37PM	Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down (Zacks) -14.06%
09:15AM	Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates (Zacks)

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krishnan Suma	President, R&D	Mar 04 '26	Sale	263.21	25,000	6,580,270	1,403,155	Mar 06 06:23 PM
Krishnan Krish S	President and CEO	Mar 04 '26	Sale	263.17	25,000	6,579,164	1,475,253	Mar 06 06:22 PM
SUMA KRISHNAN	Director	Mar 04 '26	Proposed Sale	263.80	25,000	6,595,000		Mar 04 04:40 PM
KRISH KRISHNAN	Director	Mar 04 '26	Proposed Sale	263.80	25,000	6,595,000		Mar 04 04:39 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 27 '26	Option Exercise	0.00	8,050	0	26,068	Mar 03 06:33 PM
ROMANO KATHRYN	Chief Accounting Officer	Mar 02 '26	Sale	267.60	750	200,700	22,366	Mar 03 06:33 PM
Krishnan Suma	President, R&D	Feb 27 '26	Option Exercise	0.00	40,725	0	1,509,075	Mar 03 06:33 PM
Krishnan Suma	President, R&D	Feb 27 '26	Option Exercise	0.00	26,500	0	1,436,211	Mar 03 06:33 PM
Krishnan Krish S	President and CEO	Feb 27 '26	Option Exercise	0.00	26,500	0	1,436,211	Mar 03 06:30 PM
Krishnan Krish S	President and CEO	Feb 27 '26	Option Exercise	0.00	40,725	0	1,509,075	Mar 03 06:30 PM
JANNEY DANIEL	Director	Feb 27 '26	Sale	275.59	11,803	3,252,824	73,293	Mar 03 06:28 PM
ROMANO KATHRYN	Officer	Mar 02 '26	Proposed Sale	267.60	750	200,700		Mar 02 12:56 PM
Daniel S Janney	Director	Feb 27 '26	Proposed Sale	275.59	11,803	3,252,824		Feb 27 04:41 PM
JANNEY DANIEL	Director	Feb 24 '26	Option Exercise	2.46	37,895	93,222	37,895	Feb 26 06:49 PM
JANNEY DANIEL	Director	Feb 24 '26	Sale	266.88	37,895	10,113,354	0	Feb 26 06:49 PM
JANNEY DANIEL	Director	Feb 24 '26	Sale	268.34	13,825	3,709,850	93,537	Feb 26 06:49 PM
JANNEY DANIEL	Director	Feb 26 '26	Sale	275.63	7,741	2,133,679	85,096	Feb 26 06:49 PM
JANNEY DANIEL	Director	Feb 25 '26	Sale	275.00	700	192,500	92,837	Feb 26 06:49 PM
Daniel S Janney	Director	Feb 26 '26	Proposed Sale	275.63	7,741	2,133,680		Feb 26 04:41 PM
Daniel S Janney	Director	Feb 25 '26	Proposed Sale	275.00	700	192,500		Feb 25 04:38 PM
JANNEY DANIEL	Director	Feb 24 '26	Proposed Sale	266.88	37,895	10,113,354		Feb 24 05:20 PM
Daniel S Janney	Director	Feb 24 '26	Proposed Sale	268.34	13,825	3,709,850		Feb 24 04:39 PM
ROSSI DINO A	Director	Feb 19 '26	Option Exercise	8.79	18,950	166,570	97,641	Feb 23 07:14 PM
ROSSI DINO A	Director	Feb 19 '26	Sale	261.41	18,950	4,953,694	78,691	Feb 23 07:14 PM
ROSSI DINO A	Director	Feb 19 '26	Proposed Sale	261.41	18,950	4,953,694		Feb 19 12:09 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 09 '26	Option Exercise	63.55	12,500	794,375	31,818	Feb 11 07:08 PM
ROMANO KATHRYN	Chief Accounting Officer	Feb 09 '26	Sale	272.14	12,500	3,401,705	19,318	Feb 11 07:08 PM
ROMANO KATHRYN	Officer	Feb 09 '26	Proposed Sale	276.66	12,500	3,458,250		Feb 09 04:04 PM
Krishnan Suma	President, R&D	Dec 04 '25	Sale	220.16	25,000	5,503,938	1,413,711	Dec 05 06:56 PM
Krishnan Suma	President, R&D	Dec 04 '25	Sale	220.14	25,000	5,503,395	1,483,056	Dec 05 06:56 PM
Krishnan Krish S	President and CEO	Dec 04 '25	Sale	220.16	25,000	5,503,938	1,413,711	Dec 05 06:53 PM
Krishnan Krish S	President and CEO	Dec 04 '25	Sale	220.14	25,000	5,503,509	1,483,056	Dec 05 06:53 PM
KRISH KRISHNAN	Director	Dec 04 '25	Proposed Sale	217.46	25,000	5,436,500		Dec 04 04:40 PM
SUMA KRISHNAN	Director	Dec 04 '25	Proposed Sale	217.46	25,000	5,436,500		Dec 04 04:38 PM
Krishnan Suma	President, R&D	Jul 14 '25	Sale	150.30	13,435	2,019,225	1,443,276	Jul 16 06:42 PM
Krishnan Suma	President, R&D	Jul 14 '25	Sale	150.30	13,400	2,014,015	1,512,529	Jul 16 06:42 PM
Krishnan Suma	President, R&D	Jul 15 '25	Sale	151.01	3,084	465,700	1,509,445	Jul 16 06:42 PM
Krishnan Suma	President, R&D	Jul 15 '25	Sale	150.98	3,036	458,361	1,440,240	Jul 16 06:42 PM
Krishnan Suma	President, R&D	Jul 16 '25	Sale	150.00	1,529	229,350	1,438,711	Jul 16 06:42 PM
Krishnan Suma	President, R&D	Jul 16 '25	Sale	150.00	1,389	208,350	1,508,056	Jul 16 06:42 PM
Krishnan Krish S	President and CEO	Jul 14 '25	Sale	150.30	13,435	2,019,225	1,443,276	Jul 16 06:41 PM
Krishnan Krish S	President and CEO	Jul 14 '25	Sale	150.30	13,400	2,014,015	1,512,529	Jul 16 06:41 PM
Krishnan Krish S	President and CEO	Jul 15 '25	Sale	151.01	3,084	465,700	1,509,445	Jul 16 06:41 PM
Krishnan Krish S	President and CEO	Jul 15 '25	Sale	150.98	3,036	458,361	1,440,240	Jul 16 06:41 PM
Krishnan Krish S	President and CEO	Jul 16 '25	Sale	150.00	1,529	229,350	1,438,711	Jul 16 06:41 PM
Krishnan Krish S	President and CEO	Jul 16 '25	Sale	150.00	1,389	208,350	1,508,056	Jul 16 06:41 PM
Krishnan Suma	President, R&D	Jul 10 '25	Sale	150.27	6,927	1,040,913	1,525,929	Jul 11 05:45 PM
Krishnan Suma	President, R&D	Jul 10 '25	Sale	150.28	6,800	1,021,880	1,456,711	Jul 11 05:45 PM
Krishnan Suma	President, R&D	Jul 09 '25	Sale	150.14	200	30,028	1,463,511	Jul 11 05:45 PM
Krishnan Suma	President, R&D	Jul 09 '25	Sale	150.07	200	30,014	1,532,856	Jul 11 05:45 PM
Krishnan Krish S	President and CEO	Jul 10 '25	Sale	150.27	6,927	1,040,913	1,525,929	Jul 11 05:44 PM
Krishnan Krish S	President and CEO	Jul 10 '25	Sale	150.28	6,800	1,021,880	1,456,711	Jul 11 05:44 PM
Krishnan Krish S	President and CEO	Jul 09 '25	Sale	150.14	200	30,028	1,463,511	Jul 11 05:44 PM
Krishnan Krish S	President and CEO	Jul 09 '25	Sale	150.07	200	30,014	1,532,856	Jul 11 05:44 PM
SUMA KRISHNAN	Director	Jul 09 '25	Proposed Sale	143.34	25,000	3,583,375		Jul 09 04:18 PM
KRISH KRISHNAN	Director	Jul 09 '25	Proposed Sale	143.34	25,000	3,583,375		Jul 09 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KRYS

Krystal Biotech Inc

Upgrade your Finviz experience